AstraZeneca Plc

AstraZeneca Plc

AstraZeneca Plc

Overview
Date Founded

1992

Headquarters

Cambridge Biomedical Campus,1 Francis Crick Avenue,Cambridge, Cambridgeshire CB2 0AA

Type of Company

Public

Employees (Worldwide)

70.6K

Industries

Pharmaceuticals
Wholesale: Medical Supplies & Pharmaceuticals
Wholesale: Consumer Durables
Other Manufacturing
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at AstraZeneca Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Director, Chief Executive Officer

Executive Director & Head of Global Sample Management, Discovery Sciences, R&D

Chief Financial Officer & Executive Director

General Counsel

Chief Compliance Officer

Chief Medical Officer

President, UK

Senior Vice President & Head of Research & Early Development, Oncology R&D

Vice President & Head of Spbd

Global Head of Environmental Protection

Board of Directors

Founder at Aphrae AB

Executive Director, Chief Executive Officer at AstraZeneca Plc

Director at Temasek International (USA) LLC

Former Chief Executive Officer at Avon Products, Inc.

Chief Research Officer at Firmenich SA

Chief Financial Officer & Executive Director at AstraZeneca Plc

Former Head-Genetics & Epidemiology Division at The Institute of Cancer Research

Chief Executive Officer at Brambles Ltd.

Chief Financial Officer at ABB Immobilien und Projekte GmbH

Paths to AstraZeneca Plc
Potential Connections via
Relationship Science
You
AstraZeneca Plc
Owners & Shareholders
Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Details Hidden

BIM-UK utilizes their market insights, global reach, proprietary technology, culture of information sharing and focus on risk management to deliver performance in all market environments. For their equity investments, the firm utilizes style-neutral (core and high performance), value and growth processes. They have combined a top-down and bottom-up approach for their fixed-income and balanced products. The fixed-income investment team specializes in particular market segments and focuses on quantitative analysis. Their Pinpoint system enables them to identify and track fixed-income issuers and credits. Investment teams are autonomous. Process implementation is formalized through investment committees and is reviewed monthly with the CIO, the head of performance and risk management and team leaders.

Details Hidden

BlackRock UK utilizes fixed-income strategies that are actively managed, model or index based. Actively managed fixed-income mandates generally employ an active investment style that emphasizes rotation among different types of debt on a relative value basis, specific security selection, quantitative analysis of each security and the portfolio as a whole and intensive credit analysis and review. They utilize a risk-controlled, systematic process for portfolio construction and alpha generation. Alpha sources may include security selection, duration and yield curve positioning, industry rotation, asset allocation, and currency positioning. BlackRock UK's equity platform includes a broad range of products that vary according to investment style (active, scientific and passive management), market-cap (small-, mid-, small/mid-, large- and all-cap), and geography (global, international and regional). The product range may also include sector funds, long-only and long-short portfolios, as well as products that combine different strategies to create balanced and asset allocation portfolios. For cash management portfolios, the investment process emphasizes safety and liquidity over yield. Their alternative mandates focus on sourcing and managing high-alpha investments with lower correlation to public markets and developing a holistic approach to address client needs in alternatives investing.

Recent Transactions
Details Hidden

Novartis AG, AveXis, Inc. purchase Astrazeneca Plc /Longmont Manufacturing Operations from AstraZeneca Plc

Details Hidden

Avara Pharmaceutical Services, Inc. purchases AstraZeneca SAS /Reims facility from AstraZeneca Plc

Details Hidden

Grünenthal GmbH purchases AstraZeneca Plc /Zomig Brand from AstraZeneca Plc

Transaction Advisors
Legal Advisor

Advised onZeneca Group Plc purchases Astra AB resulting in a new company AstraZeneca Plc

Legal Advisor

Advised onAstraZeneca Plc purchases Ardea Biosciences, Inc.

Investment Advisor

Advised onAstraZeneca Plc purchases MedImmune LLC

Legal Advisor

Advised onAstraZeneca Plc purchases Ardea Biosciences, Inc.

Legal Advisor

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Legal Advisor

Advised onAstraZeneca Plc purchases ZS Pharma, Inc.

Advisors & Consultants
Legal Advisor

Chief Legal Officer & Secretary at Comcast Corporation

Legal Advisor

Partner at Sidley Austin LLP

Legal Advisor

Senior Counsel at Davis Polk & Wardwell LLP

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Key Stats and Financials As of 2019
Market Capitalization
$136B
Total Enterprise Value
$139B
Earnings Per Share
$1.02
EBITDA
$5.58B
Net Profit
$1.33B
Total Debt
$17.5B
Total Equity
$14B
Revenue
$24.3B
EBITDAMargin
22.92%
Enterprise Value EBITDAOperating
24.91x
Enterprise Value / Sales
5.71x
Debt TEV
0.13x
TEVNet Income
104.3x
Three Year Compounded Annual Growth Rate Of Revenue
3.89%
Non-Profit Donations & Grants
$1,000 - $2,499
2018
$500K - $1M
2018
$1,000 - $2,499
2017
Investments
Details Hidden

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Details Hidden

Rani Therapeutics LLC develops a oral biotherapeutics technology for the oral delivery of drug molecules, including peptides, proteins, and antibodies. Its products include TNFa Inhibitors, Parathyroid Hormone, Human Growth Hormone, Somatostatin, and Basal Insulin. The company is headquartered in San Jose, CA.

Details Hidden

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Investors
Details Hidden

General Partner at Ventech SA

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Suppliers
AptarGroup, Inc. Personal Products | Crystal Lake, IL

AptarGroup, Inc. develops manufactures and sales of consumer product dispensing systems. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sell dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Sodexo SA Other Business & Consulting Services | Issy-les-moulineaux, France

Sodexo SA engages in the provision of on-site services, benefits and rewards services, and personal and home care services. It offers integrated solutions which cover a variety of working and living environments and are available in client segments which include corporate, health care, education, defense, remote sites, justice services, seniors, and sports and leisure. Sodexo was founded by Pierre Bellon in 1966 and is headquartered in Issy-les-Moulineaux, France.

Alliance Data Systems Corp. Other Business & Consulting Services | Plano, Texas

Alliance Data Systems Corp. engages in the provision of data-driven and transaction-based marketing and customer loyalty solutions. It operates through the following segments: LoyaltyOne, Epsilon and Card Services. The LoyaltyOne segment provides coalition and short-term loyalty programs. The Epsilon segment offers end-to-end, integrated marketing solutions. The Card Services offers risk management solutions, account origination, funding, transaction processing, customer care, collections, and marketing services for the company's private label and co-brand credit card programs. The company was founded in 1996 and is headquartered in Columbus, Ohio.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AstraZeneca Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AstraZeneca Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and AstraZeneca Plc.